Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Y. Kuo, M. J. Tsai, Y. H. Tsai, C. M. Chen, W. A. Chang, P. J. Wei, C. J. Yang, M. S. Huang (Kaohsiung, Taiwan). Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib. Eur Respir J 2013; 42: Suppl. 57, 4497

Member's Comments

No comment yet.

Related content which might interest you: Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Treatment of advanced non-small cell lung cancer with trofosfamide Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 ALK/EML4 translocation in non-squamous NSCLC and their predictors Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 The prognostic value of D-dimer in lung carcinoma Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Contribution of adjuvant chemotherapy in stage I pulmonary adenocarcinoma after surgical resection Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016 Influence of neoadjuvant therapy to complication rate after surgery for primary lung cancer Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016 Patient outcome and factors influencing lack of histology in patients with clinical diagnosis of lung cancer Source: Annual Congress 2013 –Quality management in thoracic oncology Year: 2013 Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Clinico-pathological prognostic factors for relapse in early stage non-small cell lung cancer after radical surgical resection Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013